You know, they say enigmas never age, but a pal is a wonderful thing. As a professional writer, I can appreciate how hard it can be to articulate dialogue well.
Investors like yourself are big into dialogue, especially if you frequent our bustling Bullboards section to converse with other likeminded savvy traders. If I could have a dialogue with anyone about investing, I’d travel back in time to talk to my dad when he was just a spunky 20-year-old in 1967 and offer him some advice from the future. It might go something like this.
Me: Hello, dad, I am your son from the future, the year 2025!
Dad: Did the aliens take over yet?
Me: Not yet, but I’ve come to tell you how you can get rich … and more importantly, get me rich in the process!
Dad: Great! How?
Me: By investing!
Dad: That sounds boring.
Me: It is, but the only thing better than having one Maserati is two, so listen up. In about 30 years, you’ve got to watch out for a company called Google!
Dad: That is a stupid name for a company.
Me: It is, but trust me, a few shares in this company when they start and you’ll be swimming in Loonies … I mean, dollar bills, or whatever.
Dad: What is Google?
Me: They make websites and apps.
Dad: What are websites and apps?
Me: It’s too hard to explain now, you’ve just got to find them and invest in them when they get on the NASDAQ in August 2004!
Dad: What’s the NASDAQ?
Me: Nevermind.
That was a fun warm up literary exercise. Let’s fast-forward to modern times.
In a market where innovation and execution separate the leaders from the laggards, three TSX-listed companies are making waves with groundbreaking achievements.
This article is a journalistic opinion piece which has been written based on independent research. It is intended to inform investors and should not be taken as a recommendation or financial advice.
From aviation milestones to cutting-edge cancer therapies, all in the face of a tougher employment economy, these three companies are capturing investor attention, some, but not all, for the right reasons.
Bombardier’s Global 7500: Is it a bird? Is it a plane? Is it a … no, it’s a plane
Bombardier’s (TSX:BBD, Forum) flagship business jet, the Global 7500, has soared into the record books — literally. The ultra-long-range jet has now set 135 speed records, the most ever achieved by a single business aircraft type. These records, recognized by the Fédération Aéronautique Internationale, include popular city-pair routes such as:
- Tokyo to San Francisco
- London to Riyadh
- Oakland to Tokyo
- Hartford to Dubai
- Tokyo to Toronto
- Montreal to Paris
The Global 7500 previously made headlines for completing the longest flight in business aviation history — an 8,225 nautical mile journey from Sydney to Detroit — and for its non-stop mission from London City Airport to Los Angeles, showcasing its short-field performance and intercontinental reach.
With a top speed of Mach 0.925 and a range of 7,700 nautical miles, the aircraft’s Smooth Flex Wing design enhances aerodynamic efficiency and reduces fuel burn. Looking ahead, Bombardier is preparing to launch the Global 8000, which will push the envelope even further with a range of 8,000 nautical miles and a top speed of Mach 0.94, designed for both performance and comfort.
Bombardier stock has risen 66.18 per cent since the year began.
Quarterhill: At least the cuts were not 25 per cent
Transportation technology provider Quarterhill (TSX:QTRH, Forum) has taken decisive steps in its turnaround strategy by laying off 100 employees — about 15 per cent of its workforce — to streamline operations and reduce costs. The move is expected to generate US$12 million in annualized savings by 2026 and aligns with the company’s goal of achieving sustainable adjusted EBITDA and operating cash flow.
CEO Chuck Myers emphasized the company’s focus on integrating assets, leadership changes, and renegotiating tolling contracts, which accounted for the bulk of Q1 2025 EBITDA losses. Despite recent challenges, Quarterhill has shown four consecutive years of revenue growth, reaching US$153.31 million in 2024, and has significantly reduced operating losses — signaling a promising trajectory toward profitable growth.
Quarterhill stock has fallen 19.51 per cent since the year began.
Oncolytics Biotech: Advancing immunotherapy with Pelareorep
Oncolytics Biotech (TSX:ONC, Forum) continues to make strides in oncology with its lead candidate, pelareorep, a systemically delivered oncolytic virus. Recent biomarker and translational data from the GOBLET and AWARE-1 studies reinforce pelareorep’s mechanism of action and its potential as a platform immunotherapeutic.
Key findings include:
- Activation of immune pathways and upregulation of interferons and PD-L1
- Conversion of “cold” tumors into “hot” immunologically active ones
- Expansion of tumor-infiltrating lymphocytes (TILs), correlating with tumor shrinkage
- Modulation of the tumor microenvironment to enhance responsiveness to immunotherapies
These results are particularly promising for immunotherapy-resistant cancers, such as pancreatic and breast cancer. With additional data readouts expected and regulatory discussions underway, Oncolytics is laying the groundwork for registration-enabled studies and a potentially transformative role in cancer treatment.
What the “Buzz”
Our Bullboards have up to 2 million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.
Get “Buzz on the Bullboards” delivered to your inbox every third Thursday!
Buzz on the Bullboards | Sign Up Here
Oncolytics stock has risen 21.05 per cent since the year began.
Keep your radar on these trailblazers
From the skies to the lab, these three companies are pushing boundaries in their respective industries. Bombardier is redefining business aviation, HPQ Silicon is pioneering sustainable materials, and Oncolytics Biotech is advancing the frontiers of cancer immunotherapy.
For investors looking for exposure to innovation-driven growth, these stocks are worth a closer look. As always, stay informed, do your due diligence, and keep your portfolio aligned with the companies shaping tomorrow’s headlines.
Get “Buzz on the Bullboards” delivered to your inbox every other Thursday!
Buzz on the Bullboards | Sign Up HereFor previous editions of Buzz on the Bullboards, click here.
Join the discussion: Find out what everybody’s saying about these stock on Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
